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1. Summary 
The history of transfusion medicine took a turn after the 
discovery of blood types and blood storage possibilities at 
the beginning of the 20th century.  Although complications as a 
result of blood product transfusions have since dramatically 
decreased, minor to fatal complications still exist and give 
reason to limit administration in situations where possible 
risks outweigh the benefits.  New guidelines have been 
published in order to reduce the number of unnecessary blood 
product transfusions.  Unfortunately past papers show that the 
new guidelines are not yet fully implemented.  In Switzerland 
no recent study has been published in regards to the 
administration of blood products. Therefore the goal of our 
retrospective study is to calculate the trend and evaluate the 
practice of transfusion medicine at the University Hospital of 
Zurich in the department of Obstetrics.   
Women who gave birth and received at least one red blood cell, 
platelet or fresh frozen plasma (FFP) transfusion where 
selected from the department’s database.  Complete information 
was found for 241 cases from January 1996 to February 2007.  
Information was collected from the department’s computer 
programs, completed and compared with archive data.  Data was 
collected in regards to: demographics, type of delivery, blood 
loss, number and type of transfusions received, hematological 
lab values, patient complications, complications during and 
after labor, and type of anemia treatment. 
Although we expected to see a decreasing trend in red blood 
cell transfusions, our results show an increasing percentage 
of patients receiving blood transfusions after the year 2004.  
Furthermore, our data shows a number of FFP, platelet and red 
blood cell (RBC) transfusions being administered 
inappropriately with discrepancies in data administration.  
Educational outreach and quality assurance checks are options, 
which could help improve the acknowledgment, understanding and 
administration of the practice of blood product transfusion in 
our clinic.  
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1.a Zusammenfassung 
Zu Beginn des 20. Jahrhunderts, mit der Entdeckung der 
Bluttypen und der Möglichkeit, Blut zu konservieren, hat sich 
die Transfusionsmedizin grundlegend verändert.  Es ist seither 
gelungen, Komplikationen nach Bluttransfusionen dramatisch zu 
reduzieren.  Trotzdem existieren noch immer zahlreiche, mit 
unter tödliche Risiken, die die Anwendung auf Situationen 
limitieren, in welchen die Vorteile mögliche Risiken 
überwiegen.  So sind denn auch Richtlinien publiziert worden, 
um die Anzahl unnötiger Blutttransfusionen zu verringern.  
Leider zeigen bisher veröffentlichte Studien, dass diese 
Richtlinien bisweilen nur teilweise zur Anwendung kommen.  In 
der Schweiz ist seit Jahren keine Studie mehr im Zusammenhang 
mit der Anwendung von Bluttransfusionen veröffentlicht worden.  
Die nun vorliegende, in der Abteilung für Geburtshilfe des 
Universitätsspitals Zürich durchgeführte, retrospektive Studie 
soll den Trend in der dort praktizierten Transfusionsmedizin 
bestimmen und die Anwendung von Bluttransfusionen auswerten. 
In die Studie aufgenommen wurden die Daten derjenigen 
Patientinnen, welchen mindestens ein Erythrozytenkonzentrat, 
eine Thrombozyten- oder FFP- (fresh frozen plasma) Transfusion 
in der obgenannten Abteilung verabreicht wurde.  In 241 dieser 
Fälle konnte auf vollständige Datenfiles der Patientinnen 
zurückgegriffen werden.  Sämtliche Fälle stammen aus der Zeit 
von Januar 1996 bis Februar 2007.  Die Informationen - dem 
Computerprogramm der Abteilung für Geburtshilfe entnommen - 
wurden anschliessend mit auf Papier vorhandenen Archivdaten 
verglichen und gegebenenfalls ergänzt.  Folgende Daten fanden 
Einzug in die Studie: demographische Daten, Geburtsart, 
Blutverlust, Anzahl und Art der verabreichten Transfusionen, 
hämatologische Laborwerte, Komplikationen der Patientinnen, 
Komplikationen während oder nach der Geburt, Art der 
Anämietherapie. 
Obwohl in der Anwendung von Bluttransfusionen von einem 
rückläufigen Trend ausgegangen werden musste, zeigen unsere 
Resultate eine Zunahme seit dem Jahr 2004.  Zusätzlich geben 
die Daten Auskunft über die Anzahl nicht adäquat applizierter 
Erythrozytenkonzentrate, Thrombozyten- und FFP-Transfusionen 
sowie über vorhandene Diskrepanzen in der Datenerfassung. 
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Eine gezielte Personal-Schulung und regelmässige Qualitäts-
Kontrollen könnten dazu beitragen, das nötige Verständnis und 
die entsprechende Sensibilisierung in der praktischen 
Anwendung und Administrierung von Bluttransfusionen an unserer 
Klinik zu erlangen. 
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2. Introduction 
Although administration of blood products has become safer 
than in the past, it remains a medical procedure that entails 
considerable risk.  Therefore appropriate use of blood 
products today concern both physicians and the public1.  As a 
consequence, several national health care organizations have 
introduced new guidelines addressing the proper administration 
of blood products2-4.  The historical “10/30 ” rule (hemoglobin 
10 g/dl /hematocrit 30%) once used as a trigger for red blood 
cell (RBC) transfusion is outdated, and new points of 
consideration have been advocated.  However, reports show that 
the practice of these new guidelines has not yet been fully 
implemented, and practices vary greatly amongst physicians and 
institutions.  Reports show up to  50% of patients being 
transfused inappropriately according to new transfusion 
guidelines5-10.  In Switzerland no recent review has been 
published, looking at the appropriateness of blood product 
transfusion.  Therefore, the goal of our retrospective study 
is to evaluate the practice of transfusion medicine at the 
University Hospital of Zurich in the department of Obstetrics.  
 
History of blood transfusions 
The first successful human-to-human blood transfusion recorded 
was performed by James Blundell in the early 1800’s, a British 
obstetrician who was alarmed by the unacceptably high numbers 
of deaths due to postpartum hemorrhage11.  Animal-to-human 
transfusions had been attempted as early as 1667 by Richard 
Lower in London and Jean Baptiste Denis in France11.  However, 
the goal of these lamb-to-human transfusions was the treatment 
of mental problems through the infusion of animal humors 
contained in blood11.  This procedure was banned the same year 
it began.  James Blundell preformed ten transfusions between 
1825 and 1830, five of which proved beneficial to his 
patients.  He thus made the connection between the potential 
benefits of transfusions in the prevention of death from 
hemorrhage11.  Considering that his success was limited to 50%, 
he strove to find alternatives such as saving the patient’s 
own shed blood, hence the beginning of autotransfusion11.  
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Jennings published a bibliography and review of 243 
transfusions performed up to 1873, also showing a complete 
recovery rate of 47%12.  In the year 1901 Landsteiner’s 
description of the ABO red cell antigen system dramatically 
reduced the risk of death from transfusion reactions13. 
Preventing coagulation for blood storage purposes was not 
possible until after 1915, when Dr. Richard Lewisohn in New 
York, found the optimum concentration of sodium citrate to mix 
with donor blood14.  One year later, F.P. Rous and J.R. Turner 
developed a citrate-glucose solution, which allowed blood to 
be stored for weeks after collection and still remain viable 
for transfusion13.  This made the establishment of the first 
blood depot possible in 1917, where type O blood was collected 
and stored, including citrate-glucose solution, in advance of 
the arrival of casualties during World War I14.   World War I 
and II increased demand and urged further research for better 
storage and supply of blood products.   
 
Based on this vast wartime experience the general opinion was 
that blood products were safe for widespread human use.  
However, infectious disease transmission was already a concern 
in the 1930’s when modern day transfusions began. The most 
frequently transmitted disease was Syphilis15.  Hepatitis soon 
followed in the 1940’s becoming the most common infectious 
risk of transfusion until screening tests became available in 
the 1970’s for Hepatitis B and early 1990s’ for Hepatitis C15.  
In 1980 the discovery of human immunodeficiency virus (HIV) 
quickly and dramatically raised awareness about the threat of 
infectious risk.  Since intensified blood donor evaluation, 
deferral of high-risk donors, and successive implementation of 
more sensitive screening tests, infectious risks of 
transfusions have been minimized particularly with respect to 
HIV and HCV transmission11,15. 
 
Transfusion Complications 
Although the maternal mortality rate has decreased 
dramatically since James Blundell’s time, according to the 
World Health Organization severe bleeding is still the most 
common cause of maternal death (25%), followed by infections 
 7
and eclampsia16.  This puts women in labor at higher risk for 
needing blood transfusions, and thus at higher risk for 
possible complications as a result of receiving blood 
products.  Complications can be divided into two groups: 
clinically symptomatic noninfectious complications and 
transfusion transmitted infectious complications.  Although 
patients may still perceive that HIV transmission is the most 
likely adverse outcome of transfusions, severe noninfectious 
complications now account for most of the significant 
morbidity and mortality from blood transfusions in developed 
countries17.  Noninfectious complications include: febrile 
nonhemolytic transfusion reaction, circulatory overload, 
transfusion related acute lung injury, acute hemolytic 
transfusion reaction, graft-versus-host disease and allergic 
reactions.  
 
Febrile nonhemolytic transfusion reactions (FNHTR) are very 
common, clinically benign complications caused by pyrectic 
cytokines either transmitted via blood transfusion or produced 
by the recipient as a reaction to the donated blood18.  They 
are characterized by a rise >1°C in temperature, which may be 
accompanied by chills, rigors, or anxiety unrelated to other 
medical conditions19.  They occur at an incidence of 
approximately 0.5% to 6% during or after RBC transfusion.  
With the use of platelet transfusions the incidence has been 
reported to be as high as 38%20. 
 
Circulatory overload is one of the most common transfusion 
complications.  One study found an incidence of 1 of 3’168 
patients transfused with RBC’s21.  Circulatory overload is the 
result of increased venous pressure due to an increase in 
blood volume from transfused products with subsequent 
congestive heart failure and pulmonary edema22.  
 
Transfusion related acute lung injury (TRALI) was listed as 
the third leading cause of transfusion-related mortality in 
198523, and the leading cause in 200424.  Diagnosis of TRALI is 
established if a patient has no preexisting acute lung injury 
(ALI) prior to transfusion, and during or within 6 hours after 
completion of the transfusion there is: acute onset of 
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respiratory distress, hypoxemia, no evidence of left atrial 
hypertension (ie. circulatory overload), and no temporal 
relationship to an alternative risk factor for ALI25.  
 
Acute hemolytic transfusion reactions (AHTR’s) due to 
incompatible blood transfusions are currently the second 
leading cause of transfusion-related mortality, with the 
majority due to ABO-incompatible RBC transfusions25 causing 
intravascular hemolysis22.  AHTR is most frequently the result 
of human error.  A survey of transfusion errors in New York 
State over a 10 year period found the erroneous administration 
to be one in every 19’000 RBC units administered, with blood 
being administered to the wrong recipient representing 38% of 
the errors26.  Overall the incidence of fatal complications due 
to erroneous administration is approximately one in every 
1'500’000 units of blood administered27. 
 
Transfusion-associated Graft-versus-host disease (TA-GVHD) is 
a life-threatening T lymphocyte mediated immune response with 
a 90-100% mortality rate, death occurring one to three weeks 
after transfusion28.  This complication is almost universally 
fatal because it targets not only the host’s or recipient’s 
endothelial lining, but the bone marrow as well22.  As a result 
TA-GVHD causes bone marrow aplasia and pancytopenia marking 
the terminal stage of this disease22.  Currently irradiation is 
the only way to prevent TA-GVHD, which inactivates T 
lymphocytes in cellular blood products22. 
 
Many screening tests have been developed since the beginning 
of modern day transfusions in order to prevent the 
transmission of diseases via blood donations.  Consequently 
the risk of acquiring a transmitted disease is low as seen in 
the table below:  
 
Bacterial Contamination 1:10’000 – 100’00018 
Hepatitis B Infection 1:100’000 – 1’000’00018 , 
1:205’00015 
Hepatitis C Infection Less than 1:10’000’00018, 
1:1’935’00015 
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HIV-Infection 1:2’135’00015, 1:2’100’00025 
 
The following screening tests are available: hepatitis B 
surface antigen, antibodies to HIV-1 and HIV-2, hepatitis C 
virus, and syphilis29.  In the USA Human T Cell Lymphotrophic 
Virus (HTLV) and West Nile Virus screens are also routinely 
performed15. 
 
The risk of bacterial contamination is often underrated. In 
allogenic blood components an estimated 1 in 3’000 platelets 
and 1 in 30’000 red blood cells are contaminated.  Serious 
septic reactions, including death in nearly a third of 
confirmed cases, were reported in approximately 1 in 100’000 
platelet transfusions and 1 in 5 million red blood cell 
transfusions15.  The risk of septic reactions potentially 
progressing to septic shock is far greater with platelets than 
with red blood cells and other blood components, due to the 
warmer storage temperature platelets require. This provides 
far better growth potential for bacteria than refrigerated red 
blood cell storage15. 
 
Literature Review 
Considering the possible complications, which can result from 
blood product transfusion, this form of therapy should only be 
applied when appropriate.  The question remains, when is the 
use of blood products appropriate and when not?  As mentioned 
earlier, although several National Health Organizations have 
published new guidelines regarding the use of blood products, 
there is no universally recognized algorithm.  Nevertheless 
when comparing new guidelines, many recommendations are equal 
or similar.  For example, a common agreement regarding the 
transfusion of RBC’s is that a patient’s hemoglobin level, 
although important, should not be the sole deciding factor 
when deciding whether to transfuse3-5,30.  Factors which should 
also be included in deciding whether the use of RBC is 
appropriate are: signs and symptoms of hypoxia, the rate of 
ongoing blood loss, evidence of end-organ compromise and the 
risk of coronary artery disease4.  Furthermore, guidelines 
offer numerical suggestions to aid in the decision of, and the 
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retrospective analysis of, appropriately transfusing blood 
products.  For example a Canadian Expert Working Group stated 
that when patients are clinically stable and not at risk for 
coronary artery disease, transfusing RBC’s is more likely to 
be beneficial when Hb is less than 6 g/dl, but not when 
greater than 8 g/dl, as long as normal blood volume is 
maintained and patient assessment is ongoing4.  The American 
Society of Anesthesiologists published similar results stating 
that RBC transfusion is rarely indicated when the hemoglobin 
concentration is greater than 10 g/dl and is almost always 
indicated when it is less than 6 g/dl2. 
New guidelines have also been published regarding the 
transfusion of fresh frozen plasma (FFP) and platelets.  
Similar to new RBC transfusion guidelines, the patient’s 
clinical situation should play a important role in the 
decision making process and numerical triggers are offered to 
help verify whether administration is appropriate or not.  FFP 
is indicated for massive blood transfusions, urgent reversal 
of Warfarin therapy, correction of known coagulation factor 
deficiencies for which specific concentrates are unavailable, 
and correction of microvascular bleeding when prothrombin and 
partial thromboplastin are over 1.5 times the normal value2.  
It is contraindicated for augmentation of plasma volume or 
albumin concentration2.  Platelets are usually required if 
surgical and obstetric patients with microvascular bleeding 
show a platelet count less than 50 x109/l and are rarely 
required when greater than 100 x109/l2.  They are also required 
in case of inherited or acquired platelet function disorders.  
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3. Patients and Methods 
Before beginning our retrospective study, a letter of approval 
was required from the ethics subcommittee for Gynecology and 
Obstetrics in Zurich.  The study was approved as StV34/2006 in 
February 2007.  We then selected patients from the database of 
the department of Obstetrics in the University Hospital of 
Zurich.  The women selected had given birth and had received 
at least one of the following blood product transfusions: RBC, 
fresh frozen plasma and/or platelets.  Patient cases were 
applicable when patient admittance occurred after January 
1996, due to incomplete patient data prior to this date.  
Using patient identification numbers and case numbers, these 
selected patients were used as the basis for our retrospective 
study.  
 
Each patient was given a new case number (1-247) and listed in 
the statistical software Excel® (Microsoft® Excel® 2004 for 
Mac Version 11.3.7).  Using two computer programs, Perinat® 
and KISIM, data was collected for each of these 247 cases and 
documented in the Excel® table.  The software Perinat® 
(Version 4.0) was developed in the department of Obstetrics 
and Gynecology at the University Hospital of Zurich.  The 
program is a clinical information system where patient 
information is listed upon admittance and completed during the 
patient’s stay in the hospital.  The program KISIM (Version 
8.11) developed by Cistec AG Zürich, stands for „Klinisches 
Information System Innere Medizin “, and is the software used 
at the University Hospital to view patient data, lab data and 
other results collected for hospital use.   
 
In our study we collected patient information for the 
following criteria: demographic data (patient’s age, week of 
pregnancy reached, parity, gravidity and number of fetus’s 
carried during pregnancy), type of delivery, blood loss during 
the operation, number and type of transfusions received, 
hemoglobin levels (before birth, after birth, before leaving 
hospital), duration of stay in hospital, patient 
complications, complications during and after labor, and type 
of anemia treatment (iron intravenous with or without 
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recombinant human erythropoetin).  For the criteria, which are 
not numerical, such as patient complications and complications 
during and after labor, a legend was first created assigning a 
number to every type of complication, so that this information 
could also be listed in the statistical computer program 
Excel®.  Complications during and after labor were defined as 
complications directly related to the action of giving birth: 
lacerations, atonic uterus, placental complications, premature 
detachment of placenta, bleeding due to placenta retention 
after birth, blood clotting problems due to a large volume of 
blood loss or because of DIC (disseminated intravascular 
coagulation) during labor.  Patient complications were defined 
as problems, which were not only specific to the action of 
giving birth: blood loss, hemoglobin under 7 g/dl, blood 
pressure problems, preeklamptic state, HELLP syndrome, and 
diseases diagnosed before pregnancy which could have effected 
the patient during the labor period.  
 
All demographic data, the type of delivery, and the number of 
fetus’s carried was taken from the computer program Perinat®.  
Estimated blood loss values were taken from the operation 
notes.  Operation notes were viewable either in Perinat® or in 
KISIM, where copies of the operation documents were viewable 
for patients who arrived later than January 2004.  The number 
of transfusions received were taken from Perinat® when 
available, and otherwise from the KISIM operation notes.  In 
order to find hemoglobin and platelet values before birth, 
after birth and when leaving the hospital, these dates and 
times were first found in the program Perinat® and then 
matched with the appropriate lab values found in KISIM.  The 
duration of stay in the hospital was calculated using 
admittance and discharge dates taken from Perinat®.  Patient 
complications and complications at birth were taken from both 
Perinat® and KISIM operation notes.  The type of anemia 
treatment was taken from Perinat®. 
 
If any information was missing in Perinat® or KISIM, the 
needed numbers and facts were accessible in the department’s 
paper archives.  In order to find the paper archive for each 
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patient, one needed to find the patient’s social insurance 
number by which each patient is filed.  
 
As mentioned earlier, the product of this data collection was 
listed in an Excel® table.  Six cases were excluded from our 
list, due to incomplete patient data, leaving us with 241 
complete cases.  Using Excel® we were able to calculate 
statistical values such as mean, median, and standard error, 
and draw several trend-lines.  
 4. Results: 
Demographic characteristics 
The average age of all the women included in our study was 
31.5 years, with a low of 17 and a high of 51 years.  The 
distribution shown in percent per age group of 5 years is 
listed in table 1.  The mean week of pregnancy reached was 
34.5 weeks. This shows that the majority of patients (69.7%) 
who required transfusions delivered preterm babies, 29.5% 
delivered term babies and only 0.4% delivered babies postterm.  
The mean parity of the women who required transfusions was 1.6 
and the mean gravidity 2.1.  Regarding the number of fetuses 
carried: 88% of the women carried one, 12% two and 0.4% 
carried three fetuses or more during pregnancy.  
 
Type of delivery: 
Of the patients receiving transfusions, a regular caesarean 
section was preformed for 68% of deliveries; another 13% 
required emergency caesarean section, making a total of 84% 
requiring a caesarean section.  15% of the women delivered 
their babies spontaneously and 5% required vaginal operative 
assistance.   Of all the women who gave birth at our clinic, 
the percentage of women having a caesarean section increased 
annually from 0.3% in 1998 to 0.4% in the year 2006.  Of these 
patients 3% received a RBC, platelet and/or FFP transfusion, 
0.9% at least one RBC transfusion. 
 
Estimated Blood Loss: 
The average blood loss per patient needing any kind of 
transfusion was 1318 mL.  The median for the same group of 
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patients was 700 mL.  The average blood loss per patient who 
required at least one RBC transfusion was higher, 2356 mL.  
The median being 2000 mL.  
 
Transfusions 
From January 1996 to February 2007, 241 women who gave birth 
at the University Hospital of Zurich received a transfusion.  
In figure 2 the percentages of women receiving transfusions 
per year are shown.  Complete data concerning the number of 
transfusions was only available after January 1999, therefore 
trend lines could only be drawn for the time between January 
1999 to December 2006.  When analyzing the data, two separate 
perspectives were used: one showing results for women who 
received any of the three types of transfusions (FFP, 
platelets, RBC), and the other showing only the women who 
received at least one RBC transfusion.  This was done in order 
to analyze the selected group as a whole, but also to gain 
results for specifically those patients who received at least 
one RBC transfusion, excluding for example women who received 
only FFP transfusions.  
 
After the year 1999 results show a decreasing trend for women 
requiring some type of transfusion until the year 2004, as 
seen in figure 3.  The peak percentage reached 1.9% in the 
year 2000, after which it continuously declined to 0.5% in 
2004.  In the years following, the trend shows an increase 
reaching 1.4% in 2006.   
 
The overall trend for women who gave birth and received at 
least one RBC transfusion was quite different, also seen in 
figure 3.  From the year 1999 to 2002 the rates increased from 
0.4% to 0.7%.  After the peak in 2002 the values dropped to a 
minimum of 0.2% in 2004.  Similar to the trend of women 
requiring some type of transfusion, the trend increased to a 
peak of 1.1% in 2006.  In figure 4 the number of patients 
receiving RBC transfusions per year is shown alongside the 
total number of RBC transfusions administered per year. 
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The second trend line drawn for transfusions was one used to 
depict the mean number of RBC transfusions used per patient.  
These results are shown in figure 5, where one can see that 
the overall trend from the year 1999 to 2006 is a decrease in 
the number of RBC transfusions used per case, beginning at a 
mean of 9.0 transfusions per patient in 1996 and ending with 
2.2 in 2007.  However, the years 2001 and 2004 stand out on 
their own with peak values of 9.3 and 8.5 transfusions per 
patient.  
When analyzing the distribution of the type of transfusion 
received by patients, again two perspectives were analyzed.  
Figure 6 shows the transfusion distribution for all 241 
patients between the years 1996 and February 2007.  Figure 7 
depicts the transfusion distribution for those patients who 
received at least one RBC transfusion.  In the first group of 
all 241 patients 32% of the transfusions administered were 
RBC, and in the second group 46% of the transfusions received 
were RBC. 
 
Of all 241 patients 14% received platelet transfusions.  The 
distribution of the patients’ lowest platelet counts can be 
seen in figure 8.  88% of the patients received FFP 
transfusions.  The distribution of the number of FFP 
transfusions used per patient can be seen in figure 9. 
 
Hemoglobin (Hb) values 
The average hemoglobin value for women receiving some type of 
transfusion was: 11.8 g/dl before birth, 8.3 g/dl after birth 
and 9.6 g/dl before leaving the hospital.  These averages were 
lower for all three categories for women who received at least 
one RBC transfusion: 11.5 g/dl before birth, 6.6 g/dl after 
birth and 8.8 g/dl before leaving the hospital. 
 
The increase in hemoglobin, per day spent in hospital after 
birth, is listed in tables 2, 3 and 4. This was highest for 
patients who received at least one RBC transfusion rising 0.4 
g/dl per day.  Patients who received no treatment or 
recombinant human erythropoietin (rhEPO) therapy with no RBC 
transfusion experienced a hemoglobin rise of 0.1 g/dl per day.  
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The average blood loss correlating to each therapy group is 
also listed in table 4.  
 
Hemoglobin values after labor were further analyzed by sorting 
all 241 patient hemoglobin values into 3 groups: hemoglobin 
values 10.0 g/dl and higher, hemoglobin values between 7.0-9.9 
g/dl, and hemoglobin values lower than 7.0 g/dl, as seen in 
figure 12.  The same was done for those patients receiving at 
least one RBC transfusion.  In the first group 34% had a 
hemoglobin value lower than 7.0 g/dl when transfused.  For 
patients who received at least one RBC transfusion 71% had a 
hemoglobin value lower than 7.0 g/dl when transfused.  This 
leaves 29% with a hemoglobin value higher than 7.0 g/dl after 
birth, receiving a transfusion including at least one RBC 
transfusion.  In figure 13 these 29% are further sorted into 4 
groups in order to show the hemoglobin distribution for those 
patients who received a RBC transfusion and had a hemoglobin 
level higher than 7.0 g/dl.   
 
Duration of stay 
The average duration of stay for women receiving some type of 
transfusion was 8.6 days and the average for women who 
received at least one RBC transfusion was slightly shorter at 
8.4 days.  For patients who received rhEPO therapy, the 
average stay was 8.7 days. When viewing the trend line seen in 
figure 14, the average stay of patients who received at least 
one RBC transfusion declined from 1996 to 2007, beginning at 
13.2 days in 1996 and ending at 7.1 days in 2007. 
 
Patient complications and complications during labor 
Patient complications were divided into 8 categories: patients 
experiencing no complication, complications due to diseases 
diagnosed before pregnancy, preeclampsia, HELLP, hemoglobin 
values lower than 7.0 g/dl during labor or after labor, 
substantial blood loss, hypotension due to blood loss, and a 
category for other complications.  The frequencies of these 
patient complications are shown in figure 15.  The three most 
frequent patient complications listed in the operation notes 
were: substantial blood loss (39%), hemoglobin value under 7.0 
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g/dl (34%) and preeclampsia (33%).  The patient complications, 
for patients who received at least one RBC, are shown on 
figure 16. 
 
Complications during or after labor were divided into nine 
categories: no complication, complications due to placenta 
retention and consequential blood loss, premature detachment 
of the placenta, other placental complications (for example 
placenta previa, accreta), lacerations during labor, atonic 
uterus, disseminated intravascular coagulation (DIC) and 
hypocoagubility due to large volumes of blood loss.  Their 
frequencies are shown in figure 17.  The three most frequent 
complications during or after labor were: atonic uterus 
(16.7%), lacerations (12.8%) and other placenta complications 
(9.3%).  Figure 19 shows the frequency of experiencing zero, 
one, two, three or 4 complications during or after labor; most 
women (43%) had no labor complications.  For women who 
received at least one RBC transfusion, the ranking for the 
different complications was similar, however the frequency for 
each higher, as seen on figure 18. 
 
Anemia Treatment 
As seen in table 5, according to Perinat® data alone 147 
patients (61%) received anemia treatment with recombinant 
human erythropoietin (Eprex®).  However table 6 shows that 
19.3% of the patients, who did not have Eprex® selected in 
Perinat®, did receive Eprex® as written in the archive data.  
Thus including archive data, 69.3% of all the women in our 
study received Eprex®.  The documentation variety and 
distribution for both medications in Perinat® (properly 
selected in designated medication field, written in procedure 
notes, or not documented) are shown in figure 20.  
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Table 1: Demographics of all 241 patients receiving any type 
of transfusion: RBC, FFP and/or platelets 
 
Average Age giving birth  SD 
Mean 31.5 0.4 
Median 32.0  
    
Age in years 
Number of 
Patients Percent 
15-19 2 0.8% 
20-24 29 12.0% 
24-29 56 23.2% 
30-34 85 35.3% 
35-40 52 21.6% 
40 and over 17 7.1% 
    
Stay in hospital (days)  SD 
Mean 8.6 0.2 
Median 8.0  
    
Pregnancy Duration  SD 
Average (weeks) 34.5 0.4 
Percent preterm (<37+0 
weeks) 69.7%  
Percent term 29.5%  
Percent postterm (> 
43+0) 0.4%  
    
Gravidity  SD 
Mean 2.1 0.1 
Median 2.0  
    
Parity  SD 
Mean 1.6 0.1 
Median 1.0  
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Table 2: Hemoglobin values, duration of stay and average 
hemoglobin increase per day for all 241 patients 
 
 Hb (g/dl) SD 
Hb-average before birth 11.8 g/dl 0.1 
Hb-average after birth 8.3 g/dl 0.2 
Hb-average at end of stay 9.6 g/dl 0.1 
Average duration of 
hospital stay 8.6 days 0.2 
Rise in Hb pro day in 
hospital 0.2 g/dl 0.0 
 
 
 
 
Table 3: Hemoglobin (Hb) values, duration of stay and average 
hemoglobin increase per day for all 97 patients receiving RBC 
transfusion(s) (with or without Eprex®) therapy 
 
 Hb (g/dl) SD 
Hb-average before birth 11.5 g/dl 0.2 
Hb-average after birth 6.6 g/dl 0.2 
Hb-average at end of stay 8.8 g/dl 0.2 
Average duration of 
hospital stay 8.4 days 0.4 
Rise in Hb per day in 
hospital 0.3 g/dl 0.0 
 
 
 
 
Table 4: Hemoglobin (Hb) increase per day according to 
treatment with either RBC transfusion(s) or Eprex® and average 
blood loss per group of patients 
 
 
Average Hb 
increase per 
day (g/dl) 
Average blood 
loss (mL) 
No Eprex® therapy, no RBC 
transfusion 0.1 531.9 
Eprex® therapy, no RBC 
tranfusion 0.1 653.3 
RBC transfusion, no Eprex® 0.4 1866.7 
RBC transfusion and Eprex® 0.3 2501.7 
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 Table 5: Number of patients where Eprex® and/or Venofer® 
therapy was listed in the Perinat® program 
 
 Number of 
patients 
Percentage of 
patients 
Eprex® selected in 
designated therapy field or 
found in procedure notes 
147 61.0% 
Venofer® selected or found 
in procedure notes 
80 33.2% 
Eprex® and Venofer® 
selected or found together 
in procedure notes 
56 23.2% 
Patients with no Eprex® 
therapy indicated 
94 39.0% 
 
 
 
 
Table 6: Number of patients receiving Eprex® therapy including 
those listed in the Perinat® program and those by whom Eprex® 
therapy was found in archive data 
 
 Number of 
patients 
Percentage of 
patients 
Patients checked in archive 
(patients with no Eprex® 
therapy indicated in the 
Perinat® program) 
94 39.0% 
Patients excluded because no 
archive files available 
11  leaving 83 
available cases 
 
Number and percentage of 83 
patients checked in archive 
who received Eprex® therapy 
16 19.3% 
Number and percentage of 
patients receiving Eprex® 
including archive data 
167 69.3% 
 
 21
Figure 1: Distribution of labor types: spontaneous, vaginal operative assistance, caesarean section and 
emergency caesarean section of all 241 patients who received a transfusion: RBC, platelets and/or FFP
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Figure 2:  Percentage of patients admitted to the department of obstetrics who received a transfusion: RBC, 
platelet, and/or FFP
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Figure 3:  Percentage of patients per year who received at least one RBC transfusion in comparison to 
percentage of patients who received any type of transfusion (RBC, platelets, FFP)
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Figure 4:  Number of patients receiving RBC transfusions per year and total number of RBC transfused per 
year
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Figure 5:  Mean and median number of RBC transfusions received per patient per year
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Figure 6: Transfusion distribution for all 241 patients who received FFP, platelet and/or RBC transfusions
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Figure 7:  Transfusion distribution for patients receiving at least one RBC transfusion
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Figure 8:  Lowest platelet count (pro µl) for patients who received at least one platelet transfusion 
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Figure 9:  Number of FFP transfusions administered per patient
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Figure 10:  Mean hemoglobin (Hb) values of all 241 patients who received any type of transfusion: before 
labor (1), after labor (2) and before leaving the hospital (3)
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Figure 11:  Mean hemoglobin (Hb) values of all 97 patients who received at least one RBC transfusion: before 
labor (1), after labor (2) and before leaving the hospital (3)
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Figure 12:  Hemoglobin (Hb) values after labor for all 241 patients receiving a transfusion: FFP, platelets 
and/or RBC transfusions
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Figure 13:  Distribution of lowest hemoglobin (Hb) values recorded for 97 patients who received at least one 
RBC transfusion
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Figure 14:  Average duration of stay per year for patients who received at least one RBC 
transfusion
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Figure 15:  Specific patient complication distribution for all 241 patients receiving
 FFP, platelet and/or RBC transfusions
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Figure 16: Specific patient complication distribution for women who received at least one 
RBC transfusion
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Figure 17:  Distribution of specific labor complications for all 241 women who received any type 
of transfusion: FFP, platelet and/or RBC transfusions
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Figure 18: Distribution of labor complications for patients who received at least one RBC 
transfusion
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Fig. 19:  Percentage of patients experiencing one, two, three or four complications during or after labor 
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Figure 20: Distribution of erythropoietin (Eprex®) and intravenous iron therapy (Venofer®) documentation in 
the computer program Perinat®
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5. Discussion 
The transfusion of blood products can be beneficial and in 
some circumstances a lifesaving therapy.  Unfortunately blood 
products also carry a risk of complications from mild to 
severe and fatal.  Having acknowledged the serious possible 
consequences, new guidelines were published to update the 
knowledge and practice of transfusion medicine. Examples of 
such guidelines are those published in the British Journal of 
Haematology, guidelines from the American Society of 
Anesthesiologists and the Canadian Expert Working Group2-4,30.  
The aim of these guidelines was to reduce the number of 
unnecessary blood transfusions and the resulting consequences. 
Reports related to these guidelines show a decreasing trend in 
the amount of transfusions being administered31-33.  Nonetheless 
they also reveal that a percentage of transfusions are still 
being administered inappropriately5-10, and that new practice 
guidelines have not yet been fully implemented.  In accordance 
to these results, our retrospective study shows a decrease in 
the transfusion trend up to 2004, however a recent increase in 
the two years following, with transfusions being administered 
inappropriately or without proper documentation. 
 
Transfusion Trends 
Over the past 20 years reports have shown a reduction in the 
rate of blood transfusions applied in obstetric practice.  A 
Swiss study published in 1980 declared 18% of postpartum women 
receiving blood transfusions31.  In the year 1990 Klapholz 
reported only 2% of women requiring blood transfusions during 
the peripartum period32.  And in the year 2006 Basket and 
O’Connell stated that the rate of blood transfusions recorded 
in deliveries over a period of 22 years dropped 8-fold, from 
1.82% to 0.25%33. 
 
In our clinic, the percentage of patients who received at 
least one RBC transfusion varied from 0.7% in the year 1999 to 
1.1% in the year 2006.  These values are similar to other 
European results. For example, the British Journal of 
Obstetrics and Gynecology reported RBC transfusion rates in 
obstetrics varying from 0.2% to 2.6%34.  Silverman et al. 
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report 0.7% of all obstetrics-related admissions receiving an 
RBC transfusion5. 
 
In our clinic the transfusion trend portrays an overall 
decrease in transfusions received by patients up to the year 
2004, as seen in figure 2.  This is true for both patients 
receiving any type of transfusion and patients receiving at 
least one RBC transfusion.  However, in contrast to the 
previous papers mentioned above, our results show an 
unexpected increase in the percentage of patients receiving 
transfusions for both groups after the year 2004.   
 
This increase in the number of transfusions administered since 
2004 is contrary to the average number of transfusions used 
per patient.  Figure 5 shows a decrease from an average of 8.5 
to 2.2 transfusions administered per patient from 2004 to 
2007.  Our value of 2.2 transfusions administered per patient 
in the year 2007 is comparable with previous results, for 
example Silverman et al. reporting a median of 2.0 
transfusions per patient5.   
 
Of the women receiving a RBC transfusion in our clinic, 81% 
had a caesarean section (including emergency caesarean 
sections) listed as their type of labor.  Several papers 
mention caesarean section as a risk factor for receiving a 
transfusion32-35.  Of all the women who gave birth in our clinic, 
the percentage who had a caesarean section increased annually 
from 0.3% in 1998 to 0.4% in the year 2006.  Of all patients 
requiring a caesarean section 3% received a transfusion, 0.9% 
at least one RBC transfusion.  These numbers are comparable to 
Gombotz’s report, showing 3% of caesarean section patients 
receiving a blood transfusion36.  Other reports show 
percentages ranging from 1% to 7%35,37,38.  
 
Besides caesarean section, several papers mention placenta 
previa as a factor increasing the odds of requiring a 
transfusion32-35.  Further obstetric complications reported to 
increase the risk of requiring a blood transfusion are: 
uterine atony, retained placenta and tissue trauma32-35.  Our 
results show that atonic uterus was the most frequent labor 
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complication for both women receiving any of RBC, platelet 
and/or FFP transfusions (16.7%) and for the group of women 
receiving at least one RBC transfusion (25.5%).  The next most 
frequent complications were lacerations, followed by placental 
retention and other placenta complications such as previa, or 
accreta.  For each complication listed the percentages are 
higher for patients receiving at least one RBC transfusion, as 
seen on figures 17 and 18. 
 
Hemoglobin (Hb) value 
Although current transfusion guidelines imply that a numerical 
trigger should not be used as the sole determining factor to 
transfuse RBC, they offer Hb values to be used alongside the 
patient’s clinical symptoms.  As mentioned in the literature 
review section, most papers agree that a RBC transfusion is 
not recommended when the Hb value is higher than 10 g/dl3, and 
almost always needed when under 6 g/dl2,4.  
Several papers have been published verifying that these new 
guidelines are also beneficial to patient outcome.  The 
largest prospective trial done was performed as a team effort 
combining 11 Canadian institutions, sponsored by the Canadian 
government.  Over 800 intensive care patients were randomly 
transfused at a liberal (10g per dl) or restrictive (7g per 
dl) transfusion trigger.  The surprising results of this study 
are the following: the overall mortality was not significantly 
different between the two groups, and there was a trend 
towards a lower mortality in the restrictive group39.  
 
In order to assess the appropriateness of the transfusions 
administered in our clinic, we chose a less restrictive Hb 
parameter of 7 g/dl, also used by past studies to determine 
the appropriateness of RBC transfusions in hospitals5.  
Consequently patients who received a RBC transfusion and had 
Hb values higher than 7 g/dl were classified as 
inappropriately transfused.  As seen in figure 8, this was the 
case for 29% of our patients.  Six percent of patients had an 
Hb value over 10 g/dl, which even by the old criteria would 
have been described as inappropriate.  These results affirm 
past reports such as Silvmerman et al. stating that up to 32% 
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of RBC units were classified as not appropriate5.  The Canadian 
Medical Association reviewed 189 articles from 1966 to 1996 
concerning the clinical practice involving RBC transfusions. 
They found rates of 4% to 66% of the transfusions to be 
unnecessary.  The CMAJ published an article in 1997 to assess 
RBC transfusion practices and to determine the impact of 
implementing recently published guidelines from the American 
College of Physicians.  According to guidelines 55.3% of 
transfusions were judged unnecessary8.  A review of Australian 
studies shows reports of 30-50% inappropriately transfused 
RBC30.  This data supports the assumption that transfusion 
practice varies greatly, that transfusions are being 
administered inappropriately according to new guidelines and 
that there is room for improvement. 
 
Blood loss 
As stated in several journals, another criteria used to judge 
the necessity of blood transfusions is blood loss3,30.  The 
British Journal of Haematology states that RBC transfusion is 
required when blood loss estimates are greater than 2000ml and 
probably required when blood loss estimates are between 1500-
2000ml3.  Of all the women in our study, 68% had an estimated 
blood loss recorded that was less than 1500ml.  Of the women 
who received at least one RBC transfusion, 31% had an 
estimated blood loss of less than 1500ml.  Taking Hb values 
into consideration, of the women who received at least one RBC 
transfusion and also had an estimated blood loss recorded that 
was less than 1500ml, 15% had an Hb value of 7 g/dl or higher, 
thus transfused inappropriately by these two criteria (blood 
loss less than 1500 ml and Hb 7 g/dl or higher).  
 
Platelet Transfusion 
Platelet transfusion poses a far greater risk for infectious 
complications than RBC transfusions15.  The American Society of 
Anesthesiologist Task Force on Blood Component Therapy 
suggested that surgical and obstetric patients with 
microvascular bleeding usually require a platelet transfusion 
if the platelet count is less than 50 x109/l and rarely require 
therapy if it is greater than 100 x109/l2.  Australian 
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guidelines post similar recommendations stating that it is 
appropriate to maintain platelet counts over 50 x109/l in 
patients undergoing surgery30.  As seen in figure 6 only 12% of 
the women who received platelets had a value below 50 x109/l 
noted as their lowest platelet count, and 54% had a platelet 
count of over 100 x109/l.  As mentioned earlier, inherited 
platelet disorders could lead to the use of platelet 
transfusions at higher platelet counts.  However, only one of 
our 241 patients had ITP (idiopathic thrombocytopenic purpura) 
recorded as a preexisting disease influencing platelet 
function.  This would suggest that a large number of the 
platelet transfusions were administered inappropriately.  
Inappropriate platelet transfusions were also found in past 
reports, for example in the review published by the 
Commonwealth of Australia, where up to 33% of platelets where 
found to be inappropriately administered, most commonly used 
for bleeding in the perioperative period30. 
 
Fresh frozen plasma (FFP) Transfusion 
Reasons for FFP transfusions are: massive transfusion (more 
than one blood volume), microvascular bleeding with elevated 
INR, TTP (thrombotic thrombocytopenic purpura) or adult HUS 
(hemolytic uremic syndrome), serious bleeding or need of 
invasive surgery in a patient with multiple coagulation-factor 
deficiencies or acquired single coagulation-factor deficiency4.  
In other words, FFP should not be used for volume expansion40 
or as a prophylactic measure in the setting of a massive 
transfusion4.  In past studies inappropriate FFP transfusions 
have been recorded at a rate as high as 83.3%6,9,30.  In our 
study the majority (59%) of transfusions administered where 
FFP.  Unfortunately we did not attempt to register PT and PTT 
in our data collection, therefore we could not retrospectively 
analyze if lab triggers where properly recorded and applied.  
However, only 26% of our patients experienced an estimated 
blood loss greater than 2000ml, and only 6.1% experienced DIC 
or hypocoagubility.  Therefore it is quite likely that a 
number of FFP transfusions were administered inappropriately.  
An article by the Medical Journal of Australia published 31% 
of FFP having been transfused inappropriately6.  Mozes found 
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FFP transfusions having the highest rate of inappropriate 
blood product transfusion, in comparison to other blood 
products, finding 83.3% inappropriate9.  It was interesting to 
see that 66% of our patients received four or more Units of 
FFP, and 84% of patients receiving FFP had a caesarian 
delivery. 
 
Recombinant human erythropoietin (rhEPO) therapy versus 
RBC transfusion 
New guidelines agree that RBC transfusions should not be 
infused for the treatment of anemia in stable patients, when 
alterative therapies with fewer potential risks are available 
and appropriate4,41.  Several studies show that recombinant 
human erythropoietin (rhEPO) combined with intravenous iron 
therapy offer an effective treatment for postpartum anemia42,43 
and can reduce the need for allogenic blood transfusions44.  
 
In our patient group we analyzed the effect of rhEPO therapy 
and RBC transfusions on the duration of hospital stay.  The 
results are shown in table 2.  The average duration of stay 
for all of our patients was 8.6 days.  Unexpectedly, the 
duration of stay was longer for the group of patients 
receiving rhEPO therapy (and no RBC transfusion) with an 
average of 8.7 days.  This could be due to the higher average 
blood loss of the patient group receiving rhEPO as shown in 
table 4.  Another confounder could be the initial Hb upon 
admittance. The group receiving rhEPO had an average Hb value 
0.13 g/dl lower than the overall average.  
 
We also analyzed the difference in the average Hb increase per 
day depending on treatment.  For those receiving no RBC 
transfusion and no rhEPO therapy the average recorded was 0.1 
g/dl per day.  To our surprise this was identical to the group 
who did receive rhEPO and no RBC transfusion.  As mentioned 
earlier, this could be due to the rhEPO therapy group’s higher 
average blood loss as seen in table 4. These findings were not 
consistent with past reports on the infuence of rhEPO. For 
example Breymann et al. reported rhEPO in combination with 
iron being more effective in treating postpartum anaemia than 
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iron therapy only45.  After 7 days the results showed an 
increase of up to 2.0 g/dl for patients receiving rhEPO in 
combination with parenteral iron, whereas patients with iron 
showed a maximum increase of 1.4 g/dl46. A confounder, which 
could have had an affect on our therapy results was the 
discrecpency of proper therapy documentation, discussed below.  
As expected, those who received a RBC transfusion showed the 
quickest Hb recovery of 0.4 g/dl per day, reflecting the 
effectiveness of RBC transfusions in emergent situations 
 
 
 
Discrepency issues 
During our study, it became obvious that certain 
administrative factors had an influence on the results of our 
retrospective study.  These also have an effect on the ongoing 
quality of patient administration.  During our study it was 
necessary to use four sources of data in order to complete 
accurate numbers for the use of blood products.  These four 
sources were: Perinat®, KISIM lab documents and operation 
notes, anesthesiologist’s reports and other paper archive 
reports. Discrepancies were noted between the different 
sources analyzed.  Although operation notes in Perinat® were 
almost always accurate in regards to when transfusions were 
used during operations, often the actual number of 
transfusions applied and the reasons behind the decision were 
missing.  Anesthesia notes were accurate in regards to the 
number of transfusions administered, however they were only 
applicable for the transfusions applied during an operation.  
If a patient received transfusions in the intensive care unit 
or in the maternity ward, these transfusions were not included 
in discharge papers.  The number of RBC transfusions was often 
listed in a slot reserved for number of FFP used or vice 
versa, which came to light after comparing paper archives with 
Perinat® information.  In regards to patient therapy, although 
Perinat® offers a designated field for patient therapy 
including separate selection options for Eprex® (rhEPO) and 
Venofer® (intravenous iron therapy) this simple documentation 
form was only complete in a small number of cases.  Often 
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Venofer® and Eprex® could be found in the procedure notes, but 
not selected in the designated field.  The variation of 
documentation (proper selection of designated field or 
inclusion in procedure notes) is shown in figure 20.  For 
example, although both Eprex® and Venofer® both have 
designated fields, not once were both medications selected, 
even though according to practice guidelines every patient who 
receives Eprex® should also receive Venofer®.  In Perinat® 147 
patients had Eprex® therapy listed, thus leaving 94 Patients 
with no Eprex® therapy, as shown in table 5.  These 94 
patients where reviewed in the archive showing 19.3% of the 
non-Eprex® patients listed in Perinat®, actually receiving 
Eprex®, as seen in table 6. 
 
 
 
What can be done 
Reports show that a brief, focused educational outreach visit 
by transfusion specialists can substantially improve the 
appropriateness of blood product use in surgery8,47.  A study 
performed on an obstetrics and gynecology service showed a 75% 
decrease in the total number of packed cells, and a 60% 
decrease in the number of patients undergoing transfusions per 
month1.  This came after a year-long process of provider 
education and quality assurance audits in 1990.  A Canadian 
Review of clinical practice literature on allogenic RBC 
transfusions found grade A1-A2 evidence that educational 
outreach programs improve RBC utilization and appropriateness 
of transfusions and also grade A1-A2 evidence for the use of 
intra-operative algorithms increasing the appropriate use of 
blood products8.  Our goal is to organize a presentation of our 
results and to educate health professionals by providing 
information sessions or information pamphlets.  The 
establishment of a transfusion-use checklist, where the reason 
for transfusion administration can easily be documented, could 
improve quality assurance.  If all doctors would be required 
to complete this checklist before or after the administration 
of every blood product, more accurate data would be available 
to ensure proper administration.  These results could lead to 
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a second retrospective study assessing the future trend of 
transfusion medicine, the influence of obligatory 
documentation and the most common reasons for transfusion 
administration.  A further goal could be the organization of a 
computer program information session for all doctors who work 
with the program Perinat®, demonstrating and explaining the 
importance of proper, complete therapy documentation.  A long-
term goal could be the establishment of an algorithm for the 
use of RBC transfusions, platelets and FFP transfusions 
specifically for the department of Obstetrics at the 
University Hospital of Zurich.  
 
Conclusion 
Although we expected to see a decreasing trend in blood 
product transfusion from the year 1996 to 2006, our results 
show an increasing percentage of patients receiving blood 
transfusions after the year 2004.  Furthermore, our data shows 
a number of FFP, platelet and RBC transfusions being 
administered inappropriately with discrepancies in data 
administration.  Educational outreach and quality assurance 
checks are options, which could help improve acknowledgment, 
understanding and administration of the practice of blood 
product transfusion in our department.  
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